Research On Glucose-Sensitive Porous Tantalum Implants

While dental implantation has become the standard treatment for tooth loss, its efficacy in diabetic patients remains limited due to impaired osseointegration and persistent inflammation. This study developed an innovative metabolically responsive drug delivery system on porous tantalum implants, utilizing aspirin's pharmacodynamic properties to achieve glucose-dependent release kinetics. 1. Fabricated a polydopamine-assisted mesoporous silica coating on porous tantalum implants for aspirin loading, with comprehensive characterization (SEM, EDS, Zeta potential) 2. In vitro evaluation: - Assessed osteogenic differentiation using ALP staining and Alizarin Red quantification - Analyzed osteogenic markers (ALP, RUNX-2, OPN) via immunofluorescence, qPCR, and Western blot - Evaluated macrophage polarization (iNOS, CD86, CD206) in RAW264.7 cell models 3. In vivo study: - Diabetic rat models were successfully established in 6-week-old male SD rats via streptozotocin (STZ) induction (Sigma, 35 mg/kg), with persistent hyperglycemia confirmed by fasting blood glucose measurements exceeding 16.7 mmol/L (Ethical approval number: YSY-DWLL-2024612). - Implanted modified porous tantalum in femoral bone - Evaluated osseointegration by micro-CT (BV/TV) and histological analysis at 8 and 12 weeks The modified implant surface demonstrated: - Glucose-responsive drug release properties - Enhanced osteogenic activity and bone matrix mineralization - Improved anti-inflammatory microenvironment The metabolic adaptive surface modification strategy developed in this study provides a new solution for implant functionalization in patients with diabetes and realizes the synergistic effect of drug release in response to blood glucose fluctuations and implant surface optimization.